Some of our recent investments

It's been a busy few months for our members: this autumn we've backed four new companies and made one re-investment, in Inicio. Here's a quick look at who they are, what they do, and why we invested, with huge thanks, as ever, to the deal leads and DD teams who did the heavy lifting!

Precision Microbubbles

(PMb) is a spinout from Imperial College London, led by CEO Dr Elizabeth Wheeler and CTO Dr Shusei Kawara, with academic co-founders Dr James Choi and Dr Sam Au and Danny Green as Chair. Its technology sorts microbubbles physically into uniform sizes for use with focused ultrasound. The main application is treating brain diseases such as cancer and Alzheimer's, where microbubbles and ultrasound briefly open the blood-brain barrier so drugs can reach parts of the brain they normally can't. The technique is already being tested in more than 30 clinical trials, but today's microbubbles come in a mix of sizes, which makes results harder to predict and control. PMb's uniform bubbles are designed to make the approach safer and more consistent. The same technology could also improve diagnostic ultrasound imaging, support research labs and help manufacture cell and gene therapies.

Why we invested: PMb sorts existing, already-approved microbubbles rather than chemically modifying them or making new ones, so its route to regulatory approval should be shorter than competing approaches. The microbubble community is small and closely connected, and PMb has already attracted significant interest without doing any marketing, leading to early pilots and partnerships. We were also impressed by the team. James Choi is one of the pioneers of ultrasound-based blood-brain barrier opening, and spent years looking for a source of uniform microbubbles before the technology was invented at Imperial. Danny Green brings decades of medtech, startup and venture capital experience as Chair. A licensing-led business model and several secondary markets give the company more than one route to revenue.

Sibstar

Sibstar, based in Winchester and founded by Jayne Sibley and Marty Orton, makes a debit card and app that help vulnerable people spend safely and independently. It's designed for people living with dementia or learning disabilities, or recovering from addiction, who want to manage their own day-to-day spending but could benefit from some support. A family member or carer can use the app to set spending limits, choose whether cash withdrawals or contactless payments are allowed, and get live notifications. That helps protect the cardholder from financial abuse and overspending, while being far more flexible than an all-or-nothing arrangement such as power of attorney. The card can offer as much or as little support as a person needs, so it can adapt as their needs change over time.

Why we invested: Sibstar has a growing social need on one side and a clear push from regulators on the other. Under the FCA's Consumer Duty, banks must identify and support their vulnerable customers, and few of them can easily build that themselves. Sibstar already works with Santander, which refers its own customers to the service, and has built partnerships with organisations including Alzheimer's Society and Mastercard. Backing from Dragons' Den investors Sara Davies and Deborah Meaden adds the kind of credibility and trust that matters a great deal in such a sensitive area. And Jayne and Marty's marketing backgrounds show: they've built a warm, trusted brand that speaks to cardholders and supporters alike, with room to grow both directly and through bank partnerships.

Inicio (re-investment)

Inicio, based in the West Midlands and led by CEO and co-founder Rachel Curtis, helps lenders, utilities and other companies understand what customers in financial difficulty can realistically afford to pay. At the heart of the service is Budgie, an FCA-regulated conversational AI assistant that guides people through the income and expenditure assessment that is the gateway to debt help. Over the phone, this can take 45 minutes or more, and many people avoid it altogether out of anxiety or embarrassment. Budgie offers a friendly, non-judgemental alternative that's available 24/7, works alongside call centre agents or replaces them entirely, and adapts its tone when it detects someone may be vulnerable. In 2024, Inicio became the first company to receive FCA permission for "passporting", meaning a customer's completed assessment can be shared with their other lenders, so they don't have to go through the whole process again for every company they owe money to.

Why we invested (again): we first backed Inicio in 2025 and we're delighted to be continuing to support it. Inicio combines real social impact with a strong commercial case. Regulators increasingly expect firms to show they assess affordability fairly, which makes Budgie a compliance tool as well as a way to cut costs and help more customers onto manageable repayment plans. The company has reached an important stage: major enterprise clients are signing up, pilots are turning into contracts, and Inicio's work is winning industry recognition. Its use of AI is carefully designed, with the language model handling the conversation and the financial calculations kept rule-based and predictable. And Rachel has an experienced leadership team and an unusually strong board behind her.

BugBiome

BugBiome, based in Norwich and founded by CEO Dr Alicia Showering and CTO Chris Mosedale, is discovering a new generation of natural alternatives to chemical insecticides. Its AvidX platform takes an unusual approach. Most discovery programmes only ask whether a substance kills a pest. BugBiome instead uses video tracking and machine learning to watch how insects behave when exposed to microbes sourced from the natural world, looking for changes in feeding, movement and reproduction. This "behavioural fingerprint" reveals promising biological actives that other approaches miss, including ones that work in several different ways at once, which makes it much harder for pests to develop resistance. Its first product, targeting aphids, has already produced promising results in glasshouse and field trials.

Why we invested: the need for alternatives to chemical insecticides is pressing. Pests are becoming resistant to existing products, conventional insecticides harm beneficial insects such as bees and persist in the environment, and regulators are restricting their use. At the same time, big crop protection companies are increasingly outsourcing discovery and looking for new, protected products. BugBiome's approach is faster and far cheaper than traditional discovery, and its capital-light model of working with major industry partners and licensing its discoveries gives it a clear route to market. We were especially impressed by Alicia, who has quickly built a strong reputation and network across AgTech in the UK, Europe and the US. The company is also backed by experienced investors, including SOSV, whose IndieBio accelerator BugBiome took part in, and Cambridge Angels.

Asothia

Asothia is fixing the way science gets funded. Researchers can spend up to half their time chasing grants, success rates are often below 20%, and generative AI is now flooding funders with applications they have little way of assessing efficiently. Founded by CEO Maya Gavin and CTO Lydia Farnham, Asothia is building a platform for both sides of this market. Researchers use it for free to create a profile and get matched with relevant opportunities from more than 13,000 live funding sources, many of which they'd never otherwise find. For funders, Asothia is building a live view of emerging talent, funding gaps and where research is heading, so they can direct their money more strategically instead of relying only on piles of written applications.

Why we invested: Asothia is tackling a real, worldwide problem at exactly the right moment, as funders and research institutions look for better ways to cope with AI-generated applications. Maya and Lydia are an outstanding pairing. Maya's Oxford doctoral research on how ideas travel across academic communities underpins Asothia's vision and has given her strong connections across UK and US research funding, while Lydia brings experience in AI evaluation and AI adoption across government. They build quickly, too: the researcher platform was live and in use before the company raised a penny. Being free for researchers and paid for by funders is a position no competitor currently occupies, and its growing base of consented researcher profiles could become a valuable, hard-to-copy asset. With a new wave of philanthropic funders looking to back science differently, we think Asothia is well placed to become an important part of how research money is allocated.

Interested?

Are you a female founder looking to pitch to us? If so apply here . Interested in becoming an angel and seeing deals like these? Find out more here.

Sarah Turner

CEO & Co-Founder of Angel Academe

https://www.angelacademe.com
Next
Next

Some 2026 deal flow stats